贵州省医药产业发展现状调查及对策研究

发布时间：2018-01-15 08:22

  本文关键词：贵州省医药产业发展现状调查及对策研究　出处：《中国药房》2017年30期 　论文类型：期刊论文

  更多相关文章： 贵州省 医药产业 发展现状 调查 对策

【摘要】：目的:为实现贵州省医药产业的可持续发展提供参考。方法:采用文献查阅、个人访谈及问卷调查等方法相结合,对贵州省医药产业发展现状进行调查和分析,进而针对存在的不足提出相应对策建议。结果:文献查阅范围包括通过百度搜索引擎获得的网络文献,政府行政部门门户网站发布的资料、文件以及中国知网、维普数据库收录的文献;个人访谈涉及贵州省食品药品监督管理局政策法规处、药品化妆品生产监管处、医疗器械监管处的5名相关管理人员;问卷调查(对象为药品生产企业)共发放问卷70份,回收有效问卷57份,有效回收率为81.4%。贵州省目前共有药品生产企业175家(有56.5%集中在贵阳市),医疗器械生产企业106家;57家受访药品生产企业中通过2010版《药品生产质量管理规范》(GMP)认证的占87.8%。贵州省中药材品种数居全国第2位,2015年中药材人工种植及野生保护抚育总面积居全国第3位,中成药工业产值占全省医药工业总产值的85.1%,但获得审批的新药中无1、2类新药、研发人员中高学历层次人才明显偏少;化学药产业的产出能力远低于全国平均水平,化学药工业产值仅占全省医药工业总产值的10%左右,且由药品生产企业主持申报的新药近年获批成功率几乎为零;生物制品产业为新兴产业,目前仅有3家生物制品生产企业;医疗器械产业生产的341个产品中Ⅰ类146个、Ⅱ类190个、Ⅲ类5个,覆盖范围较窄,生产种类较少,整体水平在全国相对落后;医药衍生品产业已有7.0%的受访药品生产企业涉足,且中医药保健养生业的发展越来越受到重视。结论:贵州省医药产业以中药民族药产业为主导,化学药、生物制品、医疗器械产业发展滞后,医药衍生品产业需更好地促进中医药与健康养生的融合;产业整体战略意识较落后,高端研发人才较缺乏,自主创新能力较弱。建议进行顶层设计,引导企业兼并、重组;发展特色医药,深度扶持小分子化学药和生物制品生产企业;深化产业政策理解,加大自主创新投入;开发新医药衍生产品,拓展医药电子商务销售渠道;拓宽产业链深度、广度和宽度,挖掘医药大数据。
[Abstract]:Objective: to provide a reference for the sustainable development of pharmaceutical industry in Guizhou Province. Methods: the current situation of pharmaceutical industry in Guizhou province was investigated and analyzed by means of literature review, personal interview and questionnaire survey. And then put forward the corresponding countermeasures and suggestions in view of the shortcomings. Results: the scope of literature access includes the search engine through Baidu network documents published by the government administration portal documents and China knowledge network. The literature included in the WIP database; The personal interview involved 5 relevant managers of Guizhou Province Food and Drug Administration Policy and Law Department, Drug and Cosmetics production Supervision Office and Medical device Supervision Office. A total of 70 questionnaires were sent out and 57 valid questionnaires were collected. The effective recovery rate is 81.4. There are 175 pharmaceutical enterprises in Guizhou province (56.5% concentrated in Guiyang City and 106 in medical device production enterprises). Of the 57 drug manufacturing enterprises surveyed, 87.8were certified by the 2010 edition of the quality Management Standard for Pharmaceutical production (GMP). Guizhou Province ranks second in the number of varieties of traditional Chinese medicinal materials in the country. In 2015, the total area of artificial cultivation and wildlife conservation of Chinese medicinal materials ranked third in the country. The output value of proprietary Chinese medicine industry accounted for 85.1% of the total value of the province's pharmaceutical industry, but none of the new drugs approved and approved included 1 or 2 new drugs. The number of R & D personnel with higher educational level is obviously less than that of R & D personnel. The output capacity of the chemical industry is far lower than the national average, and the output value of the chemical industry accounts for only about 10% of the total output value of the pharmaceutical industry of the whole province. In recent years, the success rate of new drugs approved by pharmaceutical manufacturing enterprises is almost zero. Biological products industry is a new industry, there are only three biological products production enterprises; Of 341 products produced by the medical device industry, 146 were category 鈪，

本文编号：1427547